| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802076401013 | 207640101 | FARCEF PS.INJ.SOL 1G/VIAL (IM) BTX1VIAL+1AMPX3.5ML | 3.14 | 3.29 | 4.54 |
| 05/2018 | 2802076402027 | 207640202 | FARCEF PS.INJ.SOL 1G/VIAL (IV) BTX6VIALS | 19.33 | 20.28 | 27.94 |
For the treatment of the infections (respiratory, skin, soft tissue, UTI, ENT) caused by S. pneumoniae, H. influenzae, staphylococci, S. pyogenes (group A beta-hemolytic streptococci), E. coli, P. mirabilis, Klebsiella sp, coagulase-negative staph
Ceftriaxone works by inhibiting the mucopeptide synthesis in the bacterial cell wall. The beta-lactam moiety of Ceftriaxone binds to carboxypeptidases, endopeptidases, and transpeptidases in the bacterial cytoplasmic membrane. These enzymes are involved in cell-wall synthesis and cell division. By binding to these enzymes, Ceftriaxone results in the formation of of defective cell walls and cell death.
5.8-8.7 hours
Thirty-three percent to 67% of a ceftriaxone dose was excreted in the urine as unchanged drug and the remainder was secreted in the bile and ultimately found in the feces as microbiologically inactive compounds.
* 5.78 to 13.5 L
* 0.58 - 1.45 L/h [healthy adults receiving 0.15-3 g of CEFTRIAXONE]